Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ramesh Narayanan

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Molecular Endocrinology (Baltimore, Md.)|October 7, 2015
Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral TissuesMin Pi, Karan Kapoor, Yunpeng Wu, et al.
Endocrinology|February 2, 2012
Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancerChristopher C Coss, Amanda Jones, Deanna N Parke, et al.
Nanoscale Advances|September 22, 2022
Noncontact tip-enhanced Raman spectroscopy for nanomaterials and biomedical applicationsDmitry N Voylov, Vera Bocharova, Nickolay V Lavrik, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Role of nuclear receptors in lipid dysfunction and obesity-related diseasesHollie I Swanson, Taira Wada, Wen Xie, et al.
Plos One|January 4, 2014
Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammationRamesh Narayanan, Muralimohan Yepuru, Christopher C Coss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate CancerSuriyan Ponnusamy, Yali He, Dong-Jin Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2022
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancerThirumagal Thiyagarajan, Suriyan Ponnusamy, Dong-Jin Hwang, et al.
Human Molecular Genetics|April 29, 2017
Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophySuriyan Ponnusamy, Ryan D Sullivan, Dahui You, et al.
Cancer Research|October 6, 2017
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate CancerSuriyan Ponnusamy, Christopher C Coss, Thirumagal Thiyagarajan, et al.
Cancers|April 13, 2024
FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer BurdenSydney C Joseph, Samson Eugin Simon, Margaret S Bohm, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Molecular Endocrinology (Baltimore, Md.)|October 7, 2015
Structural and Functional Evidence for Testosterone Activation of GPRC6A in Peripheral TissuesMin Pi, Karan Kapoor, Yunpeng Wu, et al.
Endocrinology|February 2, 2012
Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancerChristopher C Coss, Amanda Jones, Deanna N Parke, et al.
Nanoscale Advances|September 22, 2022
Noncontact tip-enhanced Raman spectroscopy for nanomaterials and biomedical applicationsDmitry N Voylov, Vera Bocharova, Nickolay V Lavrik, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 9, 2012
Role of nuclear receptors in lipid dysfunction and obesity-related diseasesHollie I Swanson, Taira Wada, Wen Xie, et al.
Plos One|January 4, 2014
Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammationRamesh Narayanan, Muralimohan Yepuru, Christopher C Coss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2019
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate CancerSuriyan Ponnusamy, Yali He, Dong-Jin Hwang, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 28, 2022
Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancerThirumagal Thiyagarajan, Suriyan Ponnusamy, Dong-Jin Hwang, et al.
Human Molecular Genetics|April 29, 2017
Androgen receptor agonists increase lean mass, improve cardiopulmonary functions and extend survival in preclinical models of Duchenne muscular dystrophySuriyan Ponnusamy, Ryan D Sullivan, Dahui You, et al.
Cancer Research|October 6, 2017
Novel Selective Agents for the Degradation of Androgen Receptor Variants to Treat Castration-Resistant Prostate CancerSuriyan Ponnusamy, Christopher C Coss, Thirumagal Thiyagarajan, et al.
Cancers|April 13, 2024
FXR Agonism with Bile Acid Mimetic Reduces Pre-Clinical Triple-Negative Breast Cancer BurdenSydney C Joseph, Samson Eugin Simon, Margaret S Bohm, et al.
Pageof 8